Healthcare >> CEO Interviews >> October 1, 2001
DAVID J. MAIN was appointed President and CEO of Inex Pharmaceutical
Corporation on July 1, 1999 and since that time the company has advanced
its lead product to a pivotal Phase II/III clinical trial and raised $50
million in equity financings. From 1996-1999, Mr. Main was Vice
President, Corporate Development, at Inex. Prior to joining Inex in
September 1996, Mr. Main was a Vice President at QLT Inc. of Vancouver.
He was a member of QLT's management committee and a key member of the
QLT team responsible for several pharmaceutical alliances and over $100
million raised in Canadian and US equity financings. He also serves on
the Boards of Directors of the Canadian Bacterial Diseases Network, BC
Biotech and Protiva Biotherapeutics. Mr. Main holds a Bachelor of
Science degree in Pharmacy and a Master of Business Administration
degree from the University of British Columbia. Profile
Pharmaceutical Corporation as an overview of what the company is doing
at present?
Mr. Main: Inex was founded in 1992 on a broad
